Pasar al contenido principal

DEFINIR EL MECANISMO DE ACTIVACION DE CDCP1 PARA BLOQUEAR METASTASIS DE CANCER DE MAMA TRIPLE NEGATIVO

PID2020-112760RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Rac1 activation as a potential therapeutic option in metastatic cutaneous melanoma

  • Colón-Bolea, Paula
  • García-Gómez, Rocío
  • Casar, Berta
© 2021 by the authors., Metastasis is a complex process by which cancer cells escape from the primary tumor to colonize distant organs. RAC1 is a member of the RHO family of small guanosine triphosphatases that plays an important role in cancer migration, invasion, angiogenesis and metastasis. RAC1 activation has been related to most cancers, such as cutaneous melanoma, breast, lung, and pancreatic cancer. RAC1P29S driver mutation appears in a significant number of cutaneous melanoma cases. Likewise, RAC1 is overexpressed or hyperactivated via signaling through oncogenic cell surface receptors. Thus, targeting RAC1 represents a promising strategy for cutaneous melanoma therapy, as well as for inhibition of other signaling activation that promotes resistance to targeted therapies. In this review, we focus on the role of RAC1 in metastatic cutaneous melanoma emphasizing the anti-metastatic potential of RAC1- targeting drugs., B.C. lab is supported by PIE grant (PIE-202020E007) from Consejo Superior de Investigaciones Científicas (CSIC)- MCIU, Ramón y Cajal Research Program (MCIU, RYC2018-024004-I), and MCIN grant (PID2020-112760RB-I00).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Scaffold coupling: ERK activation by transphosphorylation across different scaffold protein species

  • Martín-Vega, Ana
  • García-Gómez, Rocío
  • Herrero, Ana
  • Fuente-Vivas, Dalia de la
  • Parvathaneni, Swetha
  • Caloto, Rubén
  • Morante, Marta
  • Kriegsheim, Alex von
  • Bustelo, Xosé R.
  • Sacks, David B.
  • Casar, Berta
  • Crespo, Piero
RAS-ERK (extracellular signal–regulated kinase) pathway signals are modulated by scaffold proteins that assemble the components of different kinase tiers into a sequential phosphorylation cascade. In the prevailing model scaffold proteins function as isolated entities, where the flux of phosphorylation events progresses downstream linearly, to achieve ERK phosphorylation. We show that different types of scaffold proteins, specifically KSR1 (kinase suppressor of Ras 1) and IQGAP1 (IQ motif-containing guanosine triphosphatase activating protein 1), can bind to each other, forming a complex whereby phosphorylation reactions occur across both species. MEK (mitogen-activated protein kinase kinase) bound to IQGAP1 can phosphorylate ERK docked at KSR1, a process that we have named “trans-phosphorylation.” We also reveal that ERK trans-phosphorylation participates in KSR1-regulated adipogenesis, and it also underlies the modest cytotoxicity exhibited by KSR-directed inhibitors. Overall, we identify interactions between scaffold proteins and trans-phosphorylation as an additional level of regulation in the ERK cascade, with broad implications in signaling and the design of scaffold protein–aimed therapeutics., P.C. laboratory is supported by grant RTI2018-096658B-100 from the Spanish Ministry of Science (MICIU/AEI/FEDER, UE), a grant from Asociación Española Contra el Cancer (AECC; GCB141423113), and CIBERONC from the Instituto de Salud Carlos III (ISCIII). B.C. is funded by PID2020-112760RB-100 from MICIU, FERO 2021.03, a PIE grant from Consejo Superior de Investigaciones Científicas (CSIC)–MICIU, and the Ramón y Cajal Research Program (MICIU, RYC2018-024004-I). X.R.B. is funded by “la Caixa” Banking Foundation (HR20-00164), the Castilla-León autonomous government (CSI252P18, CSI145P20, and CLC-2017-01), the MSI (RTI2018-096481-B-100), and the Asociación Española Contra el Cancer (GC16173472GARC). D.B.S. is supported by NIH Intramural Research Program. A.v.K. is supported by the Wellcome Trust (Multiuser Equipment Grant, 208402/Z/17/Z).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DNA damage signalling histone H2AX is required for tumour growth

  • Contreras, Lizbeth
  • García-Gaipo, Lorena
  • Casar, Berta
  • Gandarillas, Alberto
Cancer most frequently develops in self-renewal tissues that are the target of genetic alterations due to mutagens or intrinsic DNA replication errors. Histone γH2AX has a critical role in the cellular DNA repair pathway cascade and contributes to genomic stability. However, the role of γH2AX in the ontology of cancer is unclear. We have investigated this issue in the epidermis, a self-renewal epithelium continuously exposed to genetic hazard and replication stress. Silencing H2AX caused cell cycle hyperactivation, impaired DNA repair and epidermal hyperplasia in the skin. However, mutagen-induced carcinogenesis was strikingly reduced in the absence of H2AX. KO tumours appeared significantly later than controls and were fewer, smaller and more benign. The stem cell marker Δp63 drastically diminished in the KO epidermis. We conclude that H2AX is required for tissue-making during both homoeostasis and tumourigenesis, possibly by contributing to the control and repair of stem cells. Therefore, although H2AX is thought to act as a tumour suppressor and our results show that it contributes to homeostasis, they also indicate that it is required for the development of cancer., This work was funded by grants from Instituto de Salud Carlos III, ISCIII/FEDER (PI17/01307, PI20/08800, Spain; AG) and from Ministerio de Innovación, Ciencia y Universidades, (MICIU PID2020/112760RB-100; BC). LC was supported by a scholarship from Consejo Nacional de Ciencia y Tecnología (CONACyT; 709426); México)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Combination of JAKi and HDACi Exerts Antiangiogenic Potential in Cutaneous T-Cell Lymphoma

  • Karagianni, Fani
  • Piperi, Christina
  • Valero-Diaz, Sara
  • Amato, Camilla
  • Vaqué, José P.
  • Casar, Berta
  • Papadavid, Evangelia
Angiogenesis plays a pivotal role in the growth and metastasis of tumors, including the development and progression of cutaneous lymphomas. The chick embryo CAM model has been utilized in various studies to assess the growth rate, angiogenic potential, and metastatic capability of different tumor types and malignant cell lines. However, the precise mechanisms of angiogenesis in CTCL and the influence of Ruxolitinib or Resminostat on angiogenesis in hematological malignancies and solid tumors are not well understood. Recent in vitro and in vivo data have demonstrated the synergistic inhibition of tumorigenesis and metastasis in experimental models of CTCL when using the combination of Resminostat (HDACi) with Ruxolitinib (JAKi). The present work aims to elucidate the effects of this combination on the tumor microenvironment’s vascular components. We investigated the effects of Ruxolitinib (JAKi) in combination with Resminostat (HDACi) treatment in transendothelial migration of CTCL cells (106 MyLa and SeAx) by using a transwell-based transendothelial migration assay and tumor angiogenesis in vivo. We used the CTCL chick embryo CAM model with xenografted tumors derived from implanted MyLa and SeAx cells and administered topically 15 μM ruxolitinib and 5 μM Resminostat every two days during a 5-day period. JAKi and HDACi inhibited CTCL cell transendothelial migration by 75% and 82% (p < 0.05) in both CTCL engrafted cells (MyLa and SeAx, respectively) compared to the untreated group. Moreover, the combination of ruxolitinib with resminostat blocked angiogenesis by significantly reducing the number of blood vessel formation by 49% and 34% in both MyLa and SeAx, respectively (p < 0.05), indicating that the proposed combination exerted significant anti-angiogenic effects in the CAM CTCL model. Overall, these data provide valuable insights into potential therapeutic strategies targeting angiogenesis in CTCL, paving the way for more effective treatment approaches in the future., This research was funded by from Ministerio de Innovación, Ciencia y Universidades, MICIU PID2020-(112760RB-100; BC), and a LA FUNDACIÓ D’ESTUDIS I RECERCA ONCOLÒGICA (FERO) grant (BFERO2021.03). S.V.-D. is a predoctoral fellow funding by Asociación Española Contra el Cancer (AECC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Kinases Inhibitors as New Therapeutic Opportunities in Cutaneous T-Cell Lymphoma

  • Valero-Diaz, Sara
  • Amato, Camilla
  • Casar, Berta
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of T-cell lymphomas characterised by high relapse rates and no curative treatments unless the allogeneic stem cell transplantation. The main complication in the management of this kind of malignancy is the variability that characterises the genetic and clinical features among the CTCL subtypes. JAK/STAT, MAPK/ERK, PI3K/Akt, and NF-kB are those signalling pathways that are found altered in CTCL and that are responsible for promoting both T-cell malignancy and the pro-tumorigenic microenvironment. Thus, targeting key players of these pathways can be an advantageous therapeutic option for CTCL. In this review, we aim to summarise the different approaches that precisely inhibit the kinases of each cited signalling. JAK inhibitors seem to be the most promising kinase inhibitors for CTCL. However, adverse events have been reported especially in patients with immunosuppression or an underlying autoimmune disease. More studies are needed, especially clinical trials, to investigate the benefits of these drugs for the treatment of cutaneous T-cell lymphomas., This research was funded by Ministerio de Innovación, Ciencia y Universidades, MICIU PID2020-(112760RB-100; BC), and LA FUNDACIÓ D’ESTUDIS I RECERCA ONCOLÒGICA (FERO) grant (BFERO2021.03). S.V.-D. is a predoctoral fellow funding by Fundación Científica de la Asociación Española Contra el Cáncer (FC AECC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ERK1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility

  • Fuente Vivas, Dalia de la
  • Cappitelli, Vincenzo
  • García-Gómez, Rocío
  • Valero-Diaz, Sara
  • Amato, Camilla
  • Rodriguéz, Javier
  • Duro-Sánchez, Santiago
  • Kriegsheim, Alex von
  • Grusch, Michael
  • Lozano, José
  • Arribas, Joaquín
  • Berta, Casar
  • Crespo, Piero
ERK1/2 mitogen-activated protein kinases (ERK) are key regulators of basic cellular processes, including proliferation, survival, and migration. Upon phosphorylation, ERK becomes activated and a portion of it dimerizes. The importance of ERK activation in specific cellular events is generally well documented, but the role played by dimerization is largely unknown. Here, we demonstrate that impeding ERK dimerization precludes cellular movement by interfering with the molecular machinery that executes the rearrangements of the actin cytoskeleton. We also show that a constitutively dimeric ERK mutant can drive cell motility per se, demonstrating that ERK dimerization is both necessary and sufficient for inducing cellular migration. Importantly, we unveil that the scaffold protein kinase suppressor of Ras 1 (KSR1) is a critical element for endowing external agonists, acting through tyrosine kinase receptors, with the capacity to induce ERK dimerization and, subsequently, to unleash cellular motion. In agreement, clinical data disclose that high KSR1 expression levels correlate with greater metastatic potential and adverse evolution of mammary tumors. Overall, our results portray both ERK dimerization and KSR1 as essential factors for the regulation of cell motility and mammary tumor dissemination., PC lab is supported by grant PID2021-126288OB-I00 and PDC2022-133569-I00 from the Spanish Ministry of Science (MICIU/AEI/FEDER, UE); CIBERONC (CB16/12/00436) from the Instituto de Salud Carlos III (ISCIII); and a grant from ASPLA S.A “Encintalo en Rosa” Initiative. BC is funded by grants from Ministerio de Innovación, Ciencia y Universidades, MICIU PID2020/112760RB-100 and La Fundació d'Estudis i Recerca Oncològica (FERO, BFERO2021.03). JA is supported by CIBERONC; Breast Cancer Research Foundation (BCRF-23-008) and Instituto de Salud Carlos III (ISCIII) (PI22/00001). AK is supported by the Wellcome Trust (Multiuser Equipment Grant, 208402/Z/17/Z). DF-V is a CIBERONC predoctoral fellow (JCSTF2105526)., Peer reviewed